Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade
This article was originally published in The Pink Sheet Daily
Executive Summary
Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.
You may also be interested in...
Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses
Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18
Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses
Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18
Lilly Cuts Arzoxifene Losses, Will Not File NDA
After initial results from a five-year, Phase III trial showed the drug fell short on key secondary outcome measures, Lilly has decided not to file the application with FDA.